Fig. 6.
![Fig. 6. Subcellular fractionation of resting, FMLP-activated, and phagocytosing human PMNs. Distribution profiles of the PLD products, PA and PEt. PMNs were labeled with 1-O-[3H] octadecyl-sn-glycero-3 phosphocholine, activated and fractionated as described in Experimental Procedures. PA and PEt were detected as previously described.38](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/91/12/10.1182_blood.v91.12.4761/4/blod41224006y.jpeg?Expires=1722707525&Signature=UjZ-uaaC4qlmekR3~~FUEmmgnSiekVsKA2pakxZbQEYPrQbuoDPDcdUl5VCPTt8e2zpxlQlK4-CHac1xun02P-Q3c0jtektouoGP1h8GKi4imsHmHGH1AqgcWOowCVdz5vsiOdVnnBKD7RG-uXhXzeni2a7Ok70i560sPGuVL3HpDuPgPPbk3gyW8wW8rqhKqtzcJRMTfZWZlKw6TP~t3ojChEVEkptPRVoYfJh7rq7zwuYpJAetgGjOn7T~Qlzki7hMlEYOYbFo1jftP62hI1Mv~1dj8pRGNh3nN-V3cYK2sw-Fq4ddZMFGLVECDtvMBnSrIpoAAbp-okBUSfT3xQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Subcellular fractionation of resting, FMLP-activated, and phagocytosing human PMNs. Distribution profiles of the PLD products, PA and PEt. PMNs were labeled with 1-O-[3H] octadecyl-sn-glycero-3 phosphocholine, activated and fractionated as described in Experimental Procedures. PA and PEt were detected as previously described.38
